Safety and Immunogenicity of Three Doses of a Neisseria Meningitidis A + C Diphtheria Conjugate Vaccine in Infants From Niger

This article, published in The Pediatric Infectious Disease Journal, reviews a study that administered three doses of a bivalent meningococcal A + C diphtheria-toxoid-conjugated vaccine (MenD), containing 1, 4, or 16 μg of each polysaccharide per dose and administered at 6, 10, and 14 weeks of age, compared with Haemophilus influenzae type b-tetanus toxoid-conjugated vaccine given with the same schedule or with a meningococcal A + C polysaccharide vaccine (MenPS) given at 10 and 14 weeks of age. The study concluded that MenD was safe among infants in Niger, and immunization led to significantly greater functional antibody activity than with MenPS. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author(s): Campagne G, Garba A, Fabre P, et al.

Published: 2000

  • Visit web page (English)

    (Located at www.ncbi.nlm.nih.gov)

    Citation: Campagne G, Garba A, Fabre P, et al. Safety and Immunogenicity of Three Doses of a Neisseria Meningitidis A + C Diphtheria Conjugate Vaccine in Infants From Niger. The Pediatric Infectious Disease Journal. 2000;19(2):144-150.

Resource types: Peer-reviewed journal

Diseases: Haemophilus influenzae type b (Hib); Meningococcus

Topics: Vaccine safety; Disease/vaccine specific information

Regions: Africa